濮阳东方医院治疗阳痿评价很不错濮阳东方医院男科治疗早泄收费比较低,濮阳东方医院评价比较好,濮阳东方医院男科治早泄值得选择,濮阳东方医院男科治疗阳痿口碑比较好,濮阳东方男科评价好吗,濮阳东方医院男科评价好不好,濮阳东方看妇科专不专业

CANBERRA, Sept. 9 (Xinhua) -- Managing other people at work triggers structural changes in the brain, protecting its memory and learning center well into old age, Australia's study revealed on Friday.Australia's University of New South Wales (UNSW) researchers have, for the first time, identified a clear link between managerial experience throughout a person's working life, and the integrity and larger size of an individual's hippocampus (the area of the brain responsible for learning and memory) at the age of 80. "We found a clear relationship between the number of employees a person may have supervised or been responsible for and the size of the hippocampus," Dr Michael Valenzuela, Leader of Regenerative Neuroscience in UNSW's School of Psychiatry, said in a statement released on Friday."This could be linked to the unique mental demands of managing people, which requires continuous problem solving, short term memory and a lot of emotional intelligence, such as the ability to put yourself in another person's shoes. Over time this could translate into the structural brain changes we observed."The findings confirmed that staying mentally active promotes brain health, potentially warding off neurodegenerative diseases such as Alzheimer's.Using MRI imagery in a cohort of 75-92 year-olds, researchers found larger hippocampal volumes in those with managerial experience compared to those without. The effect was also seen in women who had taken on managerial roles in nursing or teaching, for example.The study was presented at this week's Brain Sciences UNSW symposium Brain Plasticity The Adaptable Brain, held in Australia.

GENEVA, Aug. 10 (Xinhua) -- In a bid to prevent millions of deaths and suffering every year from malnutrition, the Geneva-based World Health Organization (WHO) launched an online initiative on Wednesday.The e-Library of Evidence for Nutrition Actions (eLENA), according to WHO, offers the latest advice on tackling the three main forms of malnutrition, including undernutrition, vitamin and mineral deficiencies, as well as overweight and obesity.The recommendations by eLENA to tackle malnutrition include promoting breastfeeding and fortifying staple foods with vitamins and minerals such as iron and folic acid for wheat and maize flours.It also recommends using multiple micronutrient powders to fortify foods for children aged between six and 23 months.To prevent anaemia, daily iron and folic supplements are advised for pregnant women, and intermittent iron and folic acid supplementation is recommended for menstruating women and preschool and school-age.While overweight and obesity affect around 1.5 billion adults over age 20, and more than 40 million children aged under five across the world, underweight is the leading risk factor for many diseases in low-income countries and represents about six percent of the world medical burden, WHO statistics showed.

BEIJING, Sept. 20 (Xinhuanet)-- Google's executive chairman Eric Schmidt is to face a Senate hearing on whether the company is abusing its dominance in Internet search, according to media reports on Tuesday.At the Wednesday's hearing before the Senate Judiciary Committee's antitrust panel, Schmidt will argue that critics are wrong to say Google gives preference to its own products, instead, Google is just trying to deliver the best-cultivated search results for users. The issue of search ranking is a touchy subject with Google, which says its algorithm is devised to give users the most useful result so they will come back.Another focal point of the hearing, which Schmidt concerned most is "scrapers", those who game its search algorithm, for example, taking commonly searched words, combine them into a nonsensical block of text and throw it up on the Web to grab eyeballs and advertising dollars.Google believes that, if scrapers succeed too often, consumers will lose confidence in search and turn to other resources, thus posing an existential threat to the company.Regulators in the U.S. and abroad have been looking into various aspects of Google's business practices since the company's 2007 purchase of ad firm DoubleClick. At the moment, European regulators are conducting an antitrust inquiry into Google's search business while the Federal Trade Commission is doing likewise. Google relies overwhelmingly on its core product, Internet search, and dominates the market for that product. It handles around two-thirds of U.S. Internet searches and more than 80 percent in many European countries, according to comScore Inc.

WELLINGTON, June 7 (Xinhua) -- Scientists in New Zealand have developed a new drug to fight previously untreatable hypoxic cancer tumors, which form in areas of the body starved of oxygen.The researchers at the Auckland University have entered an agreement for the clinical development of CEN-209, which was developed over 10 years of research, said a statement from the university Tuesday.CEN-209 was designed to enhance the effectiveness of radiotherapy and chemotherapy in solid hypoxic tumors, which were resistant to standard cancer therapies, said the statement. In lung cancer patients for example, about half of tumors had hypoxic regions.The new drug worked by damaging the DNA of hypoxic cancer cells, while leaving normal, healthy tissues alone.CEN-209 was designed and created by researchers at the university's Auckland Cancer Society Research Centre (ACSRC), using computer models of drug transport within tumors to accurately predict the anti-tumor activity of the drugs."Our computer models of drug transport developed in-house allowed the synthetic chemists to test their design theories and considerably shortened the discovery process," said Associate Professor Michael Hay, who led the ACSRC research chemists."CEN-209 improves markedly on previous agents in this class in terms of its ability to penetrate tumors, and this is reflected by its improved activity in the laboratory, when combined with long or short courses of radiotherapy," said researcher Professor Bill Wilson.Under the agreement between the university's Auckland UniServices Ltd. and California-based Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc., Centella will have exclusive rights to CEN-209, which it will develop and trial with Cancer Research UK.The work on CEN-209 is the culmination of a program initiated with funding from the U.S. National Cancer Institute, and more recently from the Maurice Wilkins Centre for Biodiscovery. Ongoing preclinical research on CEN-209 and a backup compound was funded by grants from the Auckland Medical Research Foundation, Genesis Oncology Trust and Health Research Council of New Zealand, said the statement.

WELLINGTON, June 7 (Xinhua) -- Scientists in New Zealand have developed a new drug to fight previously untreatable hypoxic cancer tumors, which form in areas of the body starved of oxygen.The researchers at the Auckland University have entered an agreement for the clinical development of CEN-209, which was developed over 10 years of research, said a statement from the university Tuesday.CEN-209 was designed to enhance the effectiveness of radiotherapy and chemotherapy in solid hypoxic tumors, which were resistant to standard cancer therapies, said the statement. In lung cancer patients for example, about half of tumors had hypoxic regions.The new drug worked by damaging the DNA of hypoxic cancer cells, while leaving normal, healthy tissues alone.CEN-209 was designed and created by researchers at the university's Auckland Cancer Society Research Centre (ACSRC), using computer models of drug transport within tumors to accurately predict the anti-tumor activity of the drugs."Our computer models of drug transport developed in-house allowed the synthetic chemists to test their design theories and considerably shortened the discovery process," said Associate Professor Michael Hay, who led the ACSRC research chemists."CEN-209 improves markedly on previous agents in this class in terms of its ability to penetrate tumors, and this is reflected by its improved activity in the laboratory, when combined with long or short courses of radiotherapy," said researcher Professor Bill Wilson.Under the agreement between the university's Auckland UniServices Ltd. and California-based Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc., Centella will have exclusive rights to CEN-209, which it will develop and trial with Cancer Research UK.The work on CEN-209 is the culmination of a program initiated with funding from the U.S. National Cancer Institute, and more recently from the Maurice Wilkins Centre for Biodiscovery. Ongoing preclinical research on CEN-209 and a backup compound was funded by grants from the Auckland Medical Research Foundation, Genesis Oncology Trust and Health Research Council of New Zealand, said the statement.